Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds

Hydroxychloroquine does not reduce the risk of dying or improve other outcomes in hospitalised patients treated for covid-19, preliminary results from the UK RECOVERY trial have shown. Announcing the results, Martin Landray, the study’s deputy chief investigator, said, “We have concluded that there...

Full description

Saved in:
Bibliographic Details
Published inBMJ Vol. 369; p. m2263
Main Author Torjesen, Ingrid
Format Journal Article Web Resource
LanguageEnglish
Published London British Medical Journal Publishing Group 08.06.2020
BMJ Publishing Group LTD
Subjects
Azithromycin
Coronaviruses
COVID-19
Dexamethasone
Hospitals
Hydroxychloroquine
Infectious diseases
Lopinavir
News
Patients
Prophylaxis
Ritonavir
United Kingdom > UK
Online AccessGet full text

Cover

More Information
Summary:Hydroxychloroquine does not reduce the risk of dying or improve other outcomes in hospitalised patients treated for covid-19, preliminary results from the UK RECOVERY trial have shown. Announcing the results, Martin Landray, the study’s deputy chief investigator, said, “We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with covid-19. We have therefore decided to stop enrolling participants to the hydroxychloroquine arm with immediate effect.” The data show the death rate at 28 days in covid-19 patients taking hydroxychloroquine is 25.7% compared with 23.5% in patients provided with only usual hospital care (hazard ratio 1.11 (95% confidence interval 0.98-1.26); P=0.10). So far 1542 patients in the trial have been randomised to hydroxychloroquine and 3132 patients randomised to usual care alone. There was also no evidence that hydroxychloroquine impacted on length of …
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1756-1833
1756-1833
DOI:10.1136/bmj.m2263